VXRT Vaxart Dashboard

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart has believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Company profile

Ticker

VXRT

Exchange

NASDAQ

Website

vaxart.com

CEO

Andrei Floroiu

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Denali Therapeutics • Exelixis ...

Former names

Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI /DE/, NABI BIOPHARMACEUTICALS, NORTH AMERICAN BIOLOGICALS INC

SEC CIK

0000072444

Corporate docs

Articles of Incorporation & Bylaws

IRS number

591212264

VXRT stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Understanding Vaxart's Unusual Options Activity

29 Jul 21

Shares of Vaxart (NASDAQ:VXRT) saw some unusual options activity on Thursday. Following the unusual option alert, the stock price moved down to $7.91.

Vaxart Stock Shoots Higher After Its Oral Vaccine Boosts Immune Response In Previously Vaccinated Subject

29 Jul 21

Vaxart Inc's (NASDAQ: VXRT)

Why Vaxart's Stock Is Surging Higher Today

29 Jul 21

Vaxart Inc (NASDAQ: VXRT) is trading higher Thursday morning after the company announced that it has shown, for the first time in clinical trials, that its oral tablet vaccine platform successfully  boosted immune responses in subjects previously vaccinated with a Vaxart oral vaccine more than a y

Vaxart Reports Has Shown For First Time In Clinical Trials Its Oral Tablet Vaccine Platform Successfully Boosted Immune Responses In Subjects Previously Vaccinated With Vaxart Oral Vaccine More Than A Year Earlier

29 Jul 21

Vaxart Inks Antiviral Asset Licensing Pact With Altesa Biosciences

7 Jul 21

Press releases

Pro users get this 30m faster

Thinking about buying stock in Sundial Growers, Cocrystal Pharma, Vaxart, Titan Medical, or Seanergy Maritime?

29 Jul 21

NEW YORK, July 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, COCP, VXRT, TMDI, and SHIP.

Vaxart Reports Boosting Immune Responses in Subjects Previously Vaccinated by a Vaxart Vaccine

29 Jul 21

SOUTH SAN FRANCISCO, Calif., July 29, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ:VXRT) today announced that it has shown for the first time in clinical trials that its oral tablet vaccine platform

Thinking about buying stock in Opiant Pharmaceuticals, RealNetworks, Vaxart, Clover Health, or Viewray?

7 Jul 21

NEW YORK, July 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OPNT, RNWK, VXRT, CLOV, and VRAY.

Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset

7 Jul 21

Thinking about buying stock in DHI Group, Pieris Pharmaceuticals, Clover Health, Workhorse Group, or Vaxart?

24 Jun 21

Calendar

6 May 21

31 Jul 21

31 Dec 21

Financial summary

Financial statements Chart VXRT financial data

Quarter (USD)	Mar 21	Dec 20	Sep 20	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Jun 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Vaxart earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	157.31M	157.31M	157.31M	157.31M	157.31M	157.31M
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	5.17M	3.75M	5.53M	3.09M
Cash used (since last report)	n/a	n/a	20.75M	15.05M	22.2M	12.42M
Cash remaining	n/a	n/a	136.56M	142.26M	135.11M	144.89M
Runway (months of cash)	n/a	n/a	26.4	37.9	24.4	46.8

Beta Read what these cash burn values mean

Recent insider trades

VXRT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
19 Jul 21	Echerd Margaret	Common Stock	Sell	Dispose S	No	Yes	8	1,800	14.4K	0
19 Jul 21	Echerd Margaret	Common Stock	Option exercise	Aquire M	No	No	0.77	1,467	1.13K	1,800
19 Jul 21	Echerd Margaret	Common Stock	Option exercise	Aquire M	No	No	5.17	333	1.72K	333
19 Jul 21	Echerd Margaret	Stock Option Common stock	Option exercise	Dispose M	No	No	0.77	1,467	1.13K	32,287
19 Jul 21	Echerd Margaret	Stock Option Common stock	Option exercise	Dispose M	No	No	5.17	333	1.72K	3,000
18 Jun 21	Finney Michael J.	Common Stock		Aquire X	No	No	1.1	181,818	200K	656,090
18 Jun 21	Finney Michael J.	Common Stock	Option exercise	Aquire M	No	No	0.68	12,700	8.64K	474,272
18 Jun 21	Finney Michael J.	Common Stock	Option exercise	Aquire M	No	No	0.68	9,000	6.12K	461,572
18 Jun 21	Finney Michael J.	Common Stock Purchase Warrant Common stock		Dispose X	No	No	1.1	181,818	200K	0
18 Jun 21	Finney Michael J.	Stock Option Common stock	Option exercise	Dispose M	No	No	0.68	12,700	8.64K	0

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

VXRT institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

26.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	153	135	+13.3%
Opened positions	45	43	+4.7%
Closed positions	27	30	-10.0%
Increased positions	48	46	+4.3%
Reduced positions	40	26	+53.8%

13F shares	Current	Prev Q	Change
Total value	378.56M	234.48M	+61.4%
Total shares	32.21M	35.46M	-9.2%
Total puts	1.94M	2.3M	-15.7%
Total calls	2.23M	2.25M	-1.1%
Total put/call ratio	0.9	1.0	-14.8%

Largest owners	Shares	Value	Change
STT State Street	8.49M	$51.34M	-10.2%
Vanguard	5.48M	$33.14M	+6.1%
BLK Blackrock	5.42M	$32.78M	+9.8%
Geode Capital Management	1.44M	$8.7M	+16.4%
Susquehanna International	1.11M	$6.72M	+40.1%
PFG Principal Financial Group Inc - Registered Shares	797.06K	$4.82M	+10.5%
NTRS Northern Trust	737.21K	$4.46M	+0.2%
Charles Schwab Investment Management	657.92K	$3.98M	+8.8%
C Citigroup	607.98K	$3.68M	+433.2%
Thrivent Financial For Lutherans	560.32K	$3.39M	+2723.3%

Largest transactions	Shares	Bought/sold	Change
Ra Capital Management	0	-2.74M	EXIT
Baker Bros. Advisors	0	-1.4M	EXIT
TROW T. Rowe Price	82.54K	-1.14M	-93.2%
STT State Street	8.49M	-958.67K	-10.2%
Thrivent Financial For Lutherans	560.32K	+540.48K	+2723.3%
C Citigroup	607.98K	+493.96K	+433.2%
BLK Blackrock	5.42M	+481.36K	+9.8%
Citadel Advisors	498.28K	+424.79K	+578.0%
Rafferty Asset Management	494.34K	+369.04K	+294.5%
Susquehanna International	1.11M	+317.94K	+40.1%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: Additionally, addressing, afford, appointed, bank, Barker, beginning, binding, boost, caption, Chan, classification, cleared, committee, conserved, contractual, counsel, counterparty, declaratory, deemed, degree, delegated, demand, demanding, denominated, dollar, dosage, eighteen, entirety, exploring, factual, feasibility, forecast, Good, identification, inducing, insignificant, instrument, intramuscular, iv, Kathleen, Lastly, lieu, Lodi, magnitude, marking, mask, maturity, maximize, modified, mutated, NaN, objective, paper, Phillip, pipeline, pivotal, pleading, Practice, prejudice, preliminary, pro, purportedly, realized, referenced, remedy, remove, resumed, retrospective, return, Sanetel, scope, se, serum, single, source, speculative, Stephen, strength, strong, submission, supermajority, sustained, unpredictability, unrealized, version, voluntarily, wearing, withdrew, workplace, wrongful, yen

Removed: absence, accreted, accretion, achievement, agent, agreed, antiviral, assessed, assuming, attractive, avoid, bore, borrowed, cautioned, Center, closing, confidence, contact, converted, covering, cumulative, damage, derived, desire, discontinued, emergency, employee, enabling, enhance, enrolling, entitle, entitling, epidemic, evidenced, evolve, exclusively, expanded, final, financed, formulation, freight, funded, geographic, globally, globe, holder, hospital, impaired, imposed, industry, initiate, interruption, LIBOR, longer, monitoring, multiplied, negatively, Oxford, placement, production, projected, promissory, protected, PRSU, rapid, ratably, receiving, recommended, reconciliation, reimbursable, relationship, rely, repaid, repayable, repayment, restructuring, seasonality, serving, simplify, site, step, suspension, test, travel, ultimate, unit, vesting, volatility, workforce

From filing 10-Q 2021 Q1